EnhanX Biopharm

EnhanX Biopharm is a clinical-stage biotechnology company specializing in the development of long-acting biologics for metabolic and endocrine diseases. The company leverages its proprietary EnhanX technology platform to engineer proteins and peptides with extended half-lives, aiming to improve patient convenience and therapeutic outcomes. Its lead candidate, EX-101, is a long-acting growth hormone currently in Phase 2 clinical trials, while its pipeline also includes multi-receptor agonists for obesity and diabetes. Headquartered in Suzhou, China, EnhanX is backed by prominent venture capital firms and focuses on addressing unmet needs in chronic disease management. By optimizing the pharmacokinetic properties of established therapeutic classes, the company seeks to create best-in-class treatments with reduced dosing frequency.